Canadian innovator Bialogics works with Riverain

AURORA, Ont., and DAYTON, Ohio – Bialogics and Riverain Technologies announced that the Bialogics AIQ Performance Monitoring framework will be integrated with the Riverain ClearRead CT cardiothoracic AI suite.

By integrating clinical findings with workflow and clinical utility data, the AIQ (AI Quality) Framework enables healthcare organizations and AI providers to adopt AI responsibly and transparently, anchoring decisions in a standardized framework of evidence-driven AI performance.

ClearRead CT is a cardiothoracic AI suite that reduces reading time and eases cognitive burden while improving the detection of missed nodules. A series of advanced AI algorithms is deployed and provide key insights and metrics on pulmonary nodules and coronary artery calcification.

This partnership represents a shared commitment to advancing AI transparency, performance, and clinical trust, enabling radiologists and health systems to understand better, measure, and improve the impact of AI in their daily practice.

“Integrating AI performance directly within the AI algorithms themselves establishes a new standard for transparency, accuracy, and accountability. By benchmarking every algorithm through a consistent and standardized methodology, we’re redefining how AI performance is understood, adopted, and optimized in lung screening and beyond”, said Jeff Vachon (pictured), president, Bialogics.

“The power of AI in diagnostic imaging grows when the patient journey is monitored and measured. Combining Bialogics AIQ framework with the ClearRead CT nodule detection and analysis tools brings new visibility into the performance of the tool and the patient journey of those with lung cancer and, in the future, other lung health applications,” said Steve Worrell, CEO, Riverain Technologies.

Key Features of the Evidence-Driven AIQ Framework:

• Real-time Monitoring: Validates AI outputs against radiologist clinical findings for ongoing quality control and assurance.
• AIQ Score: A composite, weighted performance score reflecting clinical validity and operational efficiency, tailored to disease-specific applications. AIQ Scoring calculates the measurements of core performance indicators in real-time, including Concordance/ Discordance, Positive and Negative Concordance Rates (PCR/NCR), Positive and Negative Predictive Value (PPV/NPV), and Augmented Findings Rate (AFR), enabling evidence-based AI adoption.
• Workflow Optimization Metrics: Assesses AI’s impact on report turnaround time, productivity, and radiologist workload; translating technical performance into operational value and immediate assessment of ROI.
• Bias and Drift Detection: Identifies demographic disparities and predictive drift, ensuring AI performs reliably across populations and over time.

The ClearRead CT Cardiothoracic Suite:
ClearRead CT first suppresses vessels for an unimpaired view of the chest. Then, pulmonary nodules are detected, segmented, quantified, and compared with corresponding nodules on the prior exam. Finally, coronary artery calcification is quantified using the Agatston score. ClearRead CT findings, volumetrics, and scores are then included in the radiology report.

Demos will be available at RSNA booth #5628 (Bialogics) and #4711 (Riverain).

About Bialogics
Bialogics is a leading provider of data analytics and business intelligence solutions for the healthcare industry. With a mission is to revolutionize Medical Imaging by turning data into actionable insights that drive operational excellence, enhance productivity, and improve clinical and financial outcomes.